Tag - CRBP

Developments

Corbus reports enrollment completion of dose escalation stage of Phase 1 trial

Corbus Pharmaceuticals (NASDAQ:CRBP) has announced the completion of enrollment for the dose-escalation portion of its bridging Phase 1 clinical trial of CRB-701 (SYS6002) in patients with advanced solid tumors...

October 16, 2024

Developments

Corbus Pharma updates Phase 3 systemic sclerosis study results

Corbus Pharmaceuticals (NASDAQ:CRBP) updated data from its Phase 3 study of lenabasum for the treatment of systemic sclerosis. Systemic sclerosis is an autoimmune disease characterized by inflammation and fibrosis...

November 9, 2020

Developments

Corbus Pharma lenabasum flunks Phase 2b cystic fibrosis study

Corbus Pharmaceuticals (NASDAQ:CRBP) reported disappointing topline results from its Phase 2b trial of lenabasum for the treatment of cystic fibrosis. Patients were randomized to receive either 5 mg or 20 mg of...

October 6, 2020

Markets

HCW reduces Corbus Pharma PT to $6 from $24

H.C. Wainwright slashed the price target for Corbus Pharmaceuticals (NASDAQ:CRBP) to $6 from $24 but maintained its “buy” rating after the company’s Phase 3 RESOLVE-1 trial of lenabasum in cutaneous systemic sclerosis...

September 9, 2020

Tag - CRBP

Corbus reports enrollment completion of dose escalation stage of Phase 1 trial

Corbus Pharma updates Phase 3 systemic sclerosis study results

Corbus Pharma lenabasum flunks Phase 2b cystic fibrosis study

HCW reduces Corbus Pharma PT to $6 from $24

General

More